This month, Farmak as the Ukrainian pharmaceutical market leader* has launched the renovated Production Unit of Workshop No. 3 with the longest line for packaging of medicinal products and additional manufacturing equipment from the world’s best suppliers. The investment in the project constituted USD 7.8 million.
The Company plans to expand its manufacturing capacity, since the Company increased exports by 40% last year alone, and established two international offices in the UAE and Vietnam this year.
The new production unit is planned to manufacture nasal and throat sprays, drops, oral and topical solutions used in the treatment of cold-related, fungal and cardiovascular diseases.
The length of the new manufacturing line is 30 meters. Such dimensions are attributed to its multifunctional performance required for numerous options of primary and secondary packaging. In addition, the new production unit has been equipped with much larger European-made reactors used for solution preparation.
The total number of medicinal products that will be manufactured at the renovated manufacturing facility is 21 million vials per year. While only 3 types of products were available earlier, now the number has increased to 23. Moreover, a washing machine for automated cleaning of containers and tools, as well as an isolator system for highly active substances have been installed at the production unit.
“Our mission is to develop quality and efficient medicinal products. Therefore, Farmak is constantly investing in state-of-the-art equipment, manufacturing capacity expansion and digital solutions. Today our manufacturing facilities meet the Ukrainian and European GMP standards. The strict FDA (U.S. Food and Drug Administration) requirements have been taken into account in the design, since our plans include to pass this inspection in the future,” said Volodymyr Kostiuk, Chief Executive Officer of Farmak.
Currently, the Company has 6 workshops at Kyiv plant and API Production Division in Shostka.
*based on volume of sales of medicinal products in monetary terms, according to Proxima Research
